Nephrogen develops curative genomic medicines targeting kidney and pancreatic diseases using an AI-driven platform. This platform, NeFIND TM, engineers novel gene delivery vectors that overcome tissue-specific delivery challenges inherent in genomic medicine. The resulting vectors offer superior efficiency and reduced immunogenicity compared to existing delivery systems.
Funding
$330K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Autosomal dominant polycystic kidney disease (ADPKD) affects a large population and currently lacks a definitive cure or truly effective treatment, leading to significant morbidity and mortality. Existing treatments do not halt disease progression, leaving a critical unmet need for therapies that target the underlying genetic cause of ADPKD.
Solution
Nephrogen is developing curative gene therapies for ADPKD using a platform that combines CRISPR-Cas genome editing with advanced nucleic acid delivery methods, such as adeno-associated viruses (AAVs). Their approach focuses on delivering gene therapy directly to the kidneys to correct the genetic mutations responsible for ADPKD. By targeting the source of the disease, Nephrogen aims to halt the progression of ADPKD and provide a lasting cure. The company's platform, NeFIND TM, utilizes AI and high-throughput in vivo screening to engineer novel gene delivery vectors that are more efficient and less immunogenic than existing vectors.
Target Audience
The primary target audience includes patients with autosomal dominant polycystic kidney disease (ADPKD) and the healthcare providers who treat them, such as nephrologists and genetic counselors.
Features
- CRISPR-Cas genome editing for targeted correction of ADPKD-causing mutations
- Engineered AAV vectors for efficient and specific delivery of gene therapy to the kidneys
- NeFIND TM platform for AI-driven discovery of novel gene delivery vectors
- Non-invasive method for local delivery of gene therapy to the kidney
- High-throughput in vivo screening to identify optimized gene therapy candidates